Innovative Therapeutics in Oncology and Neuroscience

27 Tumor Treating Fields Survival Benefit in GBM in Global Phase 3 Trials XOPTUNE GIO™ GBM (Newly Diagnosed) – Doubling of five-year survival rate First novel treatment in GBM approved in US and China in >15 years EF-14 PHASE 3 PIVOTAL STUDY IN NEWLY DIAGNOSED GBM Overall survival (5-year survival analysis) - 43% Probability of Survival 1.0 Optune Gio + TMZ (n=466) TMZ alone (n=229) Median OS from randomization (months) Log-rank P-value 20.9 16.0 <0.001 HR (95% CI) 0.63 (0.53-0.76) Median OS from diagnosis (months) 24.5 19.8 0.9 0.8 0.7- 0.6 0.5 0.4 Optune Gio +TMZ 43% P<0.001 Optune Gio + TMZ NEARLY HALF of people using Optune Gio + TMZ ALIVE AT 2 YEARS Optune Gio + TMZ 13% BETTER 13% survival at 5 YEARS 5% TMZ alone Current Status & Core Opportunity China approval in newly diagnosed and recurrent GBM (>45K annual incidence) in May 20201 with trial waiver 0.3 0.2- 31% TMZ alone 0.1 0.0 5% TMZ 0 6 12 18 24 30 36 42 2-year overall survival 48 5-year overall survival alone 54 60 Overall Survival (months) Sources: Novocure corporate presentation, January 2024; Globocan, 2020. Notes: The trademarks and registered trademarks within are the property of their respective owners. (1) Approvals for Optune GIO in combination with temozolomide for the treatment of patients with newly diagnosed GBM, and as a monotherapy for the treatment of patients with recurrent GBM. Clinical Data - Oncology Approved

View entire presentation